What is DexCom DXCM?
DexCom, Inc., which trades on the NASDAQ under the ticker symbol DXCM, is a prominent American medical device company specializing in the design, development, and commercialization of continuous glucose monitoring (CGM) systems. These systems are used primarily by people with diabetes to manage their blood glucose levels in real-time, offering a significant improvement over traditional finger-prick blood glucose testing. As of August 2026, DexCom has a market capitalization of approximately 32.2 billion dollars. The company's recent financial performance has been robust, with a share price of 83.45 dollars and a price-to-earnings ratio of 33.11, reflecting ongoing investor interest in its core technology and its role in the digital health sector. The company continues to lead in the innovation of wearable health monitoring devices, aiming to provide better health outcomes through improved data transparency for patients and healthcare providers globally.
Related FAQs
A common misconception is that Medicare covers the long-term cost of living in a nursing home, but it does not. Medicare is primarily designed to cover acute medical needs rather than long-term custodial or "nursing home" care.
There is absolutely no evidence that DexCom is going out of business. It is a highly successful, profitable, and well-established company in the medical device sector.
DexCom, Inc.
DexCom has, from time to time, performed targeted organizational restructuring and staffing adjustments as part of its ongoing efforts to maintain efficiency and prioritize high-growth initiatives.
DexCom stock anticipates a promising long-term future driven by the rapid global adoption of continuous glucose monitoring systems for diabetes management.
The eighty-twenty rule regarding Dexcom continuous glucose monitors and diabetes management often references blood glucose time-in-range targets.
Liquefied natural gas (LNG) pricing varies significantly depending on wholesale commodity market fluctuations, regional supply chains, and whether the fuel is purchased for industrial utility use or commercial vehicle fueling stations.
Acquiring continuous glucose monitoring systems like Dexcom affordably requires maximizing health insurance and Medicare formulary coverage, utilizing manufacturer copay savings cards, and purchasing supplies through preferred mail-order pharmacy sup...
Acetaminophen (Tylenol) is generally considered the safest over-the-counter pain reliever for individuals managing diabetes, provided it is taken within recommended dosage guidelines and under medical supervision.
DexCom is not "in trouble" in the sense of financial collapse, though it does face significant challenges typical of large-scale healthcare technology companies.
Executive compensation for the chief executive leadership guiding Dick's Sporting Goods, Inc. reflects leadership in the specialized athletic retail and sporting goods industry.
DexCom, Inc. (DXCM) operates as a leading medical device enterprise specializing in continuous glucose monitoring systems for diabetes management.
DexCom (DXCM) is a prominent leader in the continuous glucose monitoring (CGM) market, which is experiencing significant structural growth due to the rising global prevalence of diabetes and the increasing adoption of wearable medical technologies.
Yes, you can withdraw money from your Ameriprise Financial account at any time, though the exact process, timeline, and potential tax implications depend entirely on the specific type of account you hold.
Executive compensation for the Chief Executive Officer of Dick's Sporting Goods reflects robust leadership standards within the national athletic retail sector.
The expected stock price move for DexCom, Inc. heading into major corporate milestones, such as quarterly earnings releases or investor conferences, is calculated by options market participants using implied volatility metrics.
In terms of market capitalization and revenue specifically related to CGM, DexCom is a massive player; however, "Libre" is a product line manufactured by Abbott Laboratories.
The Dubai Financial Market (DFM) itself is an exchange, but it facilitates the payment of cash dividends for companies listed on its platform.
As of July 25, 2026, DexCom (DXCM) has a "Buy" consensus rating among analysts.